22 completed, 3 unknown, 2 recruiting, 1 terminated. 28 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Completed 22, Unknown 3, Recruiting 2, Terminated 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Prasugrel: new trials by email Literature Review of Prasugrel trials Research Report on Prasugrel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty. Clopidogrel, Ticagrelor, Prasugrel - Coronary Artery Disease, Percutaneous Coronary Intervention | Phase 3 | Recruiting | Cardiocentro Ticino | 355 | 2026-04-20 | 2026-05-13 |
| Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease Clopidogrel - Coronary Artery Disease, Platelet Reactivity | Phase 2 / Phase 3 | Unknown | St. Antonius Hospital | 80 | 2023-04-26 | 2023-06-02 |
| Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Edoxaban, Clopidogrel, Prasugrel - Atrial Fibrillation | Phase 3 | Completed | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 1506 | 2017-02-24 | 2020-05-06 |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide - Respiratory Tract Diseases, Influenza (Pandemic) | Phase 3 | Recruiting | UMC Utrecht | 20000 | 2016-04-11 | 2026-11-04 |
| Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome Prasugrel, Clopidogrel - Acute Coronary Syndrome, Unstable Angina | Phase 3 | Completed | University of Cologne | 49 | 2014-10-01 | 2015-06-11 |
| PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants Prasugrel, Clopidogrel - Acute Coronary Syndromes | Phase 3 | Completed | Dong-A University | 70 | 2013-10-01 | 2019-02-11 |
| A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg - Atrial Fibrillation, Percutaneous Coronary Intervention | Phase 3 | Completed | Janssen Scientific Affairs, LLC | 2124 | 2013-05-10 | 2017-09-19 |
| PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus ticagrelor, prasugrel - ST-Elevation Myocardial Infarction | Phase 3 | Completed | Gennaro Sardella | 50 | 2013-05-01 | 2017-06-28 |
| A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD) Prasugrel, Placebo - Sickle Cell Disease | Phase 3 | Terminated | Eli Lilly and Company | 341 | 2013-04-01 | 2019-09-25 |
| Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome Clopidogrel, Prasugrel - Coronary Artery Disease | Phase 3 | Unknown | Gennaro Sardella | 68 | 2013-03-01 | 2013-01-29 |
| Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis Prasugrel, Placebo - Coronary Artery Bypass | Phase 3 | Completed | VA Office of Research and Development | 84 | 2013-02-01 | 2019-10-30 |
| Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention Prasugrel, Clopidogrel - Acute Coronary Syndrome | Phase 3 | Completed | Dong-A University | 76 | 2012-09-01 | 2014-12-23 |
| High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients Clopidogrel, Prasugrel, Ticagrelor - Coronary Artery Disease | Phase 3 | Completed | University of Roma La Sapienza | 81 | 2012-07-01 | 2013-12-11 |
| Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial Clopidogrel, prasugrel - Acute Coronary Syndrome | Phase 3 | Completed | Gennaro Sardella | 30 | 2011-10-01 | 2012-03-27 |
| Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI) Point-of-Care Genetic Testing, Prasugrel - STEMI | Phase 2 / Phase 3 | Completed | Ottawa Heart Institute Research Corporation | 102 | 2011-09-01 | 2013-04-25 |
| Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention PRASUGREL, Clopidogrel - Acute Coronary Syndromes | Phase 3 | Completed | Assistance Publique Hopitaux De Marseille | 187 | 2011-07-01 | 2012-05-23 |
| Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI Prasugrel, Clopidogrel - Myocardial Infarction, STEMI | Phase 3 | Completed | Stiftung Institut fuer Herzinfarktforschung | 63 | 2011-05-01 | 2016-06-17 |
| Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention Prasugrel, Ticagrelor - Coronary Artery Disease, Acute Coronary Syndrome | Phase 3 | Completed | University of Patras | 44 | 2011-05-01 | 2012-06-22 |
| The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency Aspirin, Tirofiban, Clopidogrel - Coronary Artery Disease | Phase 3 | Unknown | Prince Sultan Cardiac Center, Adult Cardiology Department. | 200 | 2011-04-01 | 2012-05-15 |
| Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI) Prasugrel, Clopidogrel - Myocardial Infarction | Phase 3 | Completed | University of Patras | 35 | 2011-04-01 | 2011-09-30 |
Showing 20 of 28. Sign in to see all of them.
Acute Coronary Syndrome (13) · Coronary Artery Disease (9) · ST Elevation Myocardial Infarction (4) · Atrial Fibrillation (2) · Myocardial Infarction (2) · Anemia, Sickle Cell (1) · Angina, Stable (1) · Angina, Unstable (1) · Arrhythmias, Cardiac (1) · COVID-19 (1) · Community-Acquired Pneumonia (1) · Diabetes Mellitus (1) · Heart Diseases (1) · Influenza, Human (1) · Insulin Resistance (1)
Eli Lilly and Company (5) · University of Patras (5) · Gennaro Sardella (3) · Dong-A University (2) · Assistance Publique Hopitaux De Marseille (1) · Cardiocentro Ticino (1) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (1) · Janssen Scientific Affairs, LLC (1) · Ottawa Heart Institute Research Corporation (1) · Prince Sultan Cardiac Center, Adult Cardiology Department. (1) · St. Antonius Hospital (1) · Stiftung Institut fuer Herzinfarktforschung (1) · UMC Utrecht (1) · University of Cologne (1) · University of Roma La Sapienza (1)
Italy (10) · France (7) · Germany (7) · Belgium (6) · Canada (6) · Greece (6) · Netherlands (6) · South Korea (6) · United States (6) · Romania (5) · United Kingdom (5) · Czechia (4) · Hungary (4) · Poland (4) · Portugal (4)
Moo Hyun Kim, MD (2) · Andreas Gotte, Prof., MD (1) · Colin McArthur, Dr (1) · Derek Angus, Prof (1) · Derek Y F So, MD (1) · Hussein S Al-Amri, MD (1) · Jason D Roberts, MD (1) · John Marshall, Prof (1) · Lennie Derde, MD (1)
PMID 35224730, PMID 17982182, PMID 18377975, PMID 18498956, PMID 18757948, PMID 19106084, PMID 19249633, PMID 19699846, PMID 20026770, PMID 20598967, PMID 20723851, PMID 21473962, PMID 21511219, PMID 21606391, PMID 22199016, PMID 22440491, PMID 22633653, PMID 22783896, PMID 22789884, PMID 22920930, PMID 22995726, PMID 23048056, PMID 23117779, PMID 23448344, PMID 23953385, PMID 23991622, PMID 24140678, PMID 24947719, PMID 24952863, PMID 25012156, PMID 25524333, PMID 25538134, PMID 25616919, PMID 25819853, PMID 26011265, PMID 26060122, PMID 26089177, PMID 26386793, PMID 26542513, PMID 26637834, PMID 26644172, PMID 26883498, PMID 26916483, PMID 26988949, PMID 27030601, PMID 27151605, PMID 27517654, PMID 27815268, PMID 27881555, PMID 27959713
2015 (1), 2016 (1), 2023 (1)